非清髓性造血干细胞移植及嵌合体检测

Non-myeloablative Allo-geneic Stem Cell Transplantation and Chimerism Testing

目的评价非清髓性造血干细胞移植(NMSCT)的疗效及供受者嵌合体的检测。方法用氟达拉宾25mg/m2,-5d^-1d、马法兰140mg/m2?1d、抗胸腺细胞球蛋白15mg/(kg.d)-4d^+5d作为预处理方案,环胞霉素3mg/(kg.d),麦考芬酸脂15mg/(kg.d)用于GVHD的预防。为17例患者做了,并对嵌合体进行检测。结果17例患者达到了早期植入,中性粒细胞恢复至0.5×109/L,中位时间为13d,血小板恢复至30×109/L,中位时间为17d。全部供者粒细胞嵌合体形成中位时间为4周,全部供者T细胞形成中位时间为8周。结论应用氟达拉宾、马法兰、抗胸腺细胞球蛋白作为非清髓性造血干细胞移植预处理方案,可获得供者早期植入,不良反应少。

Objective To evaluate the effect transplantation （NMSCT）and test chimerism. Methods of non -myeloablative allo -genic stem cell 17 patients have been done NMSCT with Fludarabine（25mg/m^2, -5d ～ - 1d）, Melphalan （ 140mg/m^2 - 1d） and ATG （ 15mg/（ kg. d） - 4d ～ ＋ 5d）, condition regimen （ cyclosporine 3 mg/（ kg. d ） Myecophine 15 mg/（ kg. d ） for GVHD prevention ） and its chimerism have been tested. Results 17 patients were engrafted early. The median time to neutrophil 0.5 ×^109/L and platelet 30 × 10^9/L was 13 and 17days post - transplant respectively. The median time to full donor myeloid cell and T cell chimerism was 4 and 8 weeks respectively. Conclusion Fludarabine melphalan and ATG as a conditioning regimen for NMSCT is safe and is engrafted early.